Jefferies Group Weighs in on Kamada Ltd’s Q1 2018 Earnings (KMDA)

Kamada Ltd (NASDAQ:KMDA) – Equities research analysts at Jefferies Group issued their Q1 2018 EPS estimates for Kamada in a research note issued on Thursday. Jefferies Group analyst R. Denhoy anticipates that the biotechnology company will earn $0.02 per share for the quarter. Jefferies Group also issued estimates for Kamada’s Q2 2018 earnings at $0.06 EPS, FY2018 earnings at $0.23 EPS, FY2019 earnings at $0.42 EPS, FY2020 earnings at $0.62 EPS and FY2021 earnings at $0.38 EPS.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.10. Kamada had a net margin of 6.71% and a return on equity of 9.06%. The company had revenue of $35.71 million for the quarter, compared to analysts’ expectations of $32.90 million.

KMDA has been the topic of several other research reports. ValuEngine lowered shares of Kamada from a “hold” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research raised shares of Kamada from a “sell” rating to a “hold” rating in a research note on Friday. HC Wainwright reissued a “buy” rating on shares of Kamada in a research note on Thursday. Finally, Chardan Capital initiated coverage on shares of Kamada in a research note on Friday, February 2nd. They set a “buy” rating and a $7.00 price objective on the stock. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Kamada has a consensus rating of “Buy” and a consensus price target of $7.00.

Kamada (KMDA) opened at $5.00 on Monday. Kamada has a 52-week low of $3.75 and a 52-week high of $8.61. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.73 and a current ratio of 3.30. The stock has a market cap of $201.32, a PE ratio of 29.41 and a beta of 1.14.

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC bought a new stake in Kamada during the third quarter worth about $112,000. Worth Venture Partners LLC bought a new stake in Kamada during the third quarter worth about $246,000. Navellier & Associates Inc bought a new stake in Kamada during the second quarter worth about $303,000. Analyst IMS Investment Management Services Ltd. boosted its stake in Kamada by 125.5% during the third quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in Kamada by 6.5% during the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares in the last quarter. 6.26% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Jefferies Group Weighs in on Kamada Ltd’s Q1 2018 Earnings (KMDA)” was first reported by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/02/12/jefferies-group-weighs-in-on-kamada-ltds-q1-2018-earnings-kmda.html.

About Kamada

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply